The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•5 May 2026•

1 min read

Avalo Therapeutics Reports Positive Phase 2 Results for Hidradenitis Suppurativa Treatment

Key Facts

1Avalo Therapeutics announced that its Phase 2 LOTUS trial of abdakibart successfully met its primary endpoint for treating hidradenitis suppurativa.

Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial evaluating abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa. The trial successfully met its primary endpoint at both studied doses, demonstrating the efficacy and safety profile of the IL-1β based treatment. Following these successful outcomes, the company plans to transition the candidate into a registrational Phase 3 program. This clinical milestone marks a significant step forward for the biotech firm as it seeks regulatory approval for its lead asset. The positive data underscores the potential of abdakibart to address unmet medical needs in chronic inflammatory skin conditions.